Mektovi (binimetinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Mektovi (binimetinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
□ Locally advanced melanoma □ Unresectable melanoma □ Metastatic melanoma □ Metastatic colorectal cancer □ Other diagnosis: _____ICD-10:_____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Clinical Information:

Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? □ Yes □ No

For <u>Melanoma diagnoses</u>, answer the following:

Does patient have a BRAF V_{600E} mutation? □ Yes □ No *Submit chart documentation.*

Does patient have a BRAF V_{600K}mutation? □ Yes □ No *Submit chart documentation.*

Does patient have both BRAF V_{600E} and a BRAF V_{600K}mutation? □ Yes □ No *Submit chart documentation.*

Is patient's tumor Stage IIIB, IIIC, or IV? □ Yes □ No *Submit chart documentation.*

Has patient been previously treated for their melanoma? □ Yes □ No *Submit chart documentation.*

Has patient failed on only one previous first-line immunotherapy? □ Yes □ No *Submit chart documentation.*

Has patient been previously treated with a BRAF inhibitor? □ Yes □ No *Submit chart documentation.*

Has patient been previously treated with a MEK inhibitor? □ Yes □ No *Submit chart documentation.*

Has patient been previously treated with a systemic chemotherapy? □ Yes □ No *Submit chart documentation.*

Will patient use Braftovi(encorafenib) concomitantly with Mektovi (binimetinib)? □ Yes □ No
Submit chart documentation.

For <u>diagnosis of metastatic colorectal cancer</u>, answer the following:

Does patient have a BRAF V_{600E} mutation? □ Yes □ No *Submit chart documentation.*

Has the disease progressed after only one and no more than two previous treatment regimens? □ Yes □ No

Has patient been previously treated with a BRAF inhibitor? □ Yes □ No *Submit chart documentation.*

Mektovi (binimetinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has patient been previously treated with a MEK inhibitor? □ **Yes** □ **No** ***Submit chart documentation.***

Has the patient been previously treated with an EGFR inhibitor? □ **Yes** □ **No** ***Submit chart documentation.***

Will Mektovi be used in combination with the BRAF inhibitor Braftovi® (encorafenib)? □ **Yes** □ **No**

Will Mektovi be used in combinaiton with the EGFR inhibitor Erbitux® (cetuximab)? □ **Yes** □ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP – 4201
P.O. Box 64811
St. Paul, MN 55164-0811